PYXS (Pyxis Oncology) Market Value to Book Value Ratio

Official company branding of Pyxis Oncology Inc. (PYXS)

The price trend visualization for Pyxis Oncology, Inc. (PYXS) allows for an assessment of how strict FDA oversight and the cost of ADC drug development impact the share price, which is currently 10.25. The business relies on unique patents and a significant financial barrier to entry. High research costs and the risk of clinical trial failure weed out smaller players. The stable management of Lara Sullivan effectively allocates capital to drive innovation.

pyxisoncology.com (PYXS): Capitalization to Book Value Ratio from 07/04/2022 to 10/28/2026

Financial and market metric breakdowns for Pyxis Oncology, Inc. (PYXS)

- price and consensus price forecast:
Price Chart pyxisoncology.com|PYXS - Analyst Median Target
- market capitalization data:
Market Value Pyxis|PYXS - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Pyxis Oncology|PYXS - Accounting Capitalization|Market Capitalization to Book Value Ratio pyxisoncology.com|PYXS - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Pyxis Oncology, Inc.|PYXS - Long-Term Liabilities to Capital|Short-Term Debt to Equity pyxisoncology.com|PYXS - Company Debts|Debt to Book Capitalization Ratio Pyxis|PYXS - Long-Term Debt|Company Short-Term Debts Pyxis Oncology
Fundamental valuation:Pyxis Oncology Inc.
Brand item of pyxisoncology.com

A comparative asset analysis requires evaluating the market premium over net assets via the ratio of market capitalization to book value. This metric measures the market premium to book value, which is critical for Pyxis Oncology, Inc. (PYXS) given its focus on costly ADC drug development, reflecting investor expectations regarding the company's scientific potential through the market-to-book premium coefficient.

Competitor analysis

ImmunityBio, Inc. - Market Value to Book Value Ratio|IMCR (immunocore.com) - Market Capitalization to Book Value|Market Value to Book Value Ratio JANX (Janux Therapeutics, Inc.)|Market-to-Book Ratio RCUS|Market Value to Book Value Ratio Zymeworks Corp ZYME|Capitalization to Book Value Ratio Tango Therapeutics Corp (TNGX)|Iovance Biotherapeutics - Market Capitalization to Book Value Ratio|immatics.com - Market Cap to Net Assets Ratio|XNCR (Xencor) - Market Value to Book Value Ratio|CMPX: Market-to-Book Ratio|Replimune Corp (REPL) - Market Value to Book Value Ratio|LYEL (Lyell Pharma) - Market Value to Book Value Ratio|Market Value to Book Value Ratio IPHA (Innate Pharma S.A.)|Market-to-Book Ratio Compugen Limited|IOBT: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Sutro Biopharma Inc. STRO|INKT: Market Cap to Net Assets Ratio|HOWL - Market-to-Book Ratio|Market Cap to Net Assets Ratio Immix (IMMX)|ALXO - Market Value to Book Value|Cue Biopharma - Market Capitalization to Book Value Ratio|PDSB (PDS Biotechnology Corporation) - Market Capitalization to Book Value|Market Value to Book Value Ratio SONN|Market Cap to Net Assets Ratio MAIA|Market Value to Book Value Ratio LIMN (Liminatus Pharma)|Market Cap to Net Assets Ratio lavatherapeutics.com LVTX|Market Cap to Net Assets Ratio NXTC (NextCure)|Leap Therapeutics Inc - Market Capitalization to Book Value Ratio|Intensity Tx (INTS) - Market Value to Book Value Ratio|SNSE: Capitalization to Book Value Ratio|Market Value to Book Value Ratio TOVX|Market-to-Book Ratio Gritstone bio|Kineta - Market Cap to Net Assets Ratio|Market Value to Equity Ratio NexImmune Inc (NEXI)|Market Cap to Net Assets Ratio Turnstone Biologics|Market Cap to Book Value Multiple Vaccinex Inc (VCNX)|Market Capitalization to Book Value Ratio Harpoon Therapeutics